| abstract |
FIELD: organic chemistry, medicine, pharmacy. n SUBSTANCE: invention relates to compounds of the formula (I): wherein Ar represents phenyl substituted with a group taken among isobutyl, benzoyl, isopropyl, styryl, pentyl, (2,6-dichlorophenyl)-amino-group, α-hydroxyethyl, α-hydroxybenzyl, α-methylbenzyl and α-hydroxy-α-methylbenzyl; R represents hydrogen atom; X means linear (C 1 -C 6 )-alkylene, (C 4 -C 6 )-alkenylene, (C 4 -C 6 )-alkynylene optionally substituted with group -CO 2 R 3 wherein R 3 means hydrogen atom, group (CH 2 ) m -B-(CH 2 ) n wherein B means oxygen atom; m = 0; n means a whole number 2; or B means group -CONH; m means a whole number 1; n means a whole number 2 and so on; R 1 and R 2 are taken independently among group comprising hydrogen atom, linear (C 1 -C 4 )-alkyl, hydroxy-(C 2 -C 3 )-alkyl and so on. Invention proposes a method for preparing compounds of the formula (I). Invention proposes inhibitors of C5-induced hemotaxis of polymorphonuclear leukocytes and monocytes representing (R)-2-arylpropionic acid omega-aminoalkylamides of the formula (I). Also, invention relates to a pharmaceutical composition possessing inhibitory activity with respect to hemotaxis of polymorphonuclear leukocytes and monocytes and comprising compounds of the formula (I) in mixture with suitable carrier. Proposes (R)-2-arylpropionic acid omega-alkylamides are useful for inhibition of hemotaxic activation induced C5a and other hemotaxic proteins. n EFFECT: improved preparing method, valuable medicinal properties of compounds and composition. n 18 cl, 3 tbl, 23 ex |